Abstract
Interleukin-6 (IL-6) has emerged as a potential therapeutic target in rheumatoid arthritis (RA). This is based on the greater understanding of the role this cytokine can play in various aspects of the immunopathphysiology of RA. Recently, theory has been put into practice with the assessment of IL-6 inhibitors in clinical trials. The largest amount of data to date comes from trials of the humanized anti-IL-6 receptor antibody tocilizumab. Studies worldwide have demonstrated the clinical efficacy of this agent in patients with RA.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
